A Phase Ib/IIa Study of Romidepsin in Combination With Lenalidomide in Adults With Relapsed or Refractory Lymphomas and Myeloma

Trial Profile

A Phase Ib/IIa Study of Romidepsin in Combination With Lenalidomide in Adults With Relapsed or Refractory Lymphomas and Myeloma

Active, no longer recruiting
Phase of Trial: Phase I/II

Latest Information Update: 16 Dec 2016

At a glance

  • Drugs Lenalidomide (Primary) ; Romidepsin (Primary)
  • Indications B cell lymphoma; Hodgkin's disease; Multiple myeloma; T cell lymphoma
  • Focus Adverse reactions
  • Most Recent Events

    • 12 Dec 2016 Status changed from recruiting to active, no longer recruiting.
    • 06 Apr 2016 Planned number of patients changed from 68 to 67 as reported by ClinicalTrials.gov record.
    • 06 Apr 2016 Planned End Date changed from 1 Dec 2016 to 1 Dec 2017 as reported by ClinicalTrials.gov record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top